Considerations in the management of bipolar disorder in women

Australian and New Zealand Journal of Psychiatry

Volumn 39, Issue 8, 2005, Pages 662-673

  Barnes, Caryl ^a,b   Mitchell, Philip ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

Bipolar disorder; Gender; Sex; Treatment; Women

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CHLORPROMAZINE; CITALOPRAM; CLOZAPINE; CONJUGATED ESTROGEN; DOXEPIN; ESTRADIOL; ESTROGEN; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; OMEGA 3 FATTY ACID; ORAL CONTRACEPTIVE AGENT; PAROXETINE; PROGESTERONE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; VERAPAMIL; ZIPRASIDONE;

ALOPECIA; ANENCEPHALUS; ANOVULATION; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; BODY WEIGHT DISORDER; BREAST FEEDING; CLIMACTERIUM; COLIC; COMORBIDITY; CONGENITAL HYPOTHYROIDISM; CONGENITAL MALFORMATION; CRANIOFACIAL MALFORMATION; CYANOSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG MILK LEVEL; DRUG SAFETY; EBSTEIN ANOMALY; ELECTROCONVULSIVE THERAPY; FEMALE; FLUID RETENTION; HEART DISEASE; HUMAN; HYPERANDROGENISM; HYPERBILIRUBINEMIA; HYPERINSULINEMIA; HYPERPROLACTINEMIA; HYPOTHERMIA; HYPOTHYROIDISM; INFANTILE HYPOTONIA; INTRAUTERINE GROWTH RETARDATION; LIVER DYSFUNCTION; LIVER TOXICITY; MANIA; MENSTRUAL CYCLE; MENSTRUATION DISORDER; MENTAL HEALTH CARE; MIXED MANIA AND DEPRESSION; NEPHROGENIC DIABETES INSIPIDUS; NEURAL TUBE DEFECT; OSTEOPOROSIS; OVARY POLYCYSTIC DISEASE; POSTMENOPAUSE; PREGNANCY; PREVALENCE; PROGNOSIS; PUERPERAL PSYCHOSIS; RAPID CYCLING BIPOLAR DISORDER; RESPIRATION DEPRESSION; RESTLESSNESS; REVIEW; SEIZURE; SEX DIFFERENCE; SEXUAL DYSFUNCTION; SPONTANEOUS ABORTION; SUICIDE ATTEMPT; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TERATOGENICITY; THYROID DISEASE; TREATMENT PLANNING; WEIGHT GAIN; WOMEN'S HEALTH; HORMONE SUBSTITUTION; METHODOLOGY; PHYSIOLOGY; PSYCHOLOGICAL ASPECT;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; ELECTROCONVULSIVE THERAPY; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MENSTRUAL CYCLE; POSTMENOPAUSE;

EID: 33644646784     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1111/j.1440-1614.2005.01650.x     Document Type: Review

References (106)

1. Kessler RC, McGonagle KA, Zhao S et al. Lifetime prevalence of DSM-III-R psychiatric disorders in the United States. Archives of General Psychiatry 1994; 51: 8-19.
2. Viguera AC, Baldessarini RJ, Tondo L. Response to lithium maintenance treatment in bipolar disorders: Comparison of women and men. Bipolar Disorders 2001; 3: 245-252.
3. Weissman MM, Bland RC, Canino GJ et al. Cross-national epidemiology of major depression and bipolar disorder. The Journal of the American Medical Association 1996; 276: 293-299.
4. Baldessarini RJ, Tondo L, Hennen J. Treatment delays in bipolar disorders. American Journal of Psychiatry 1999; 5: 811.
5. Angst J, Gamma A. Prevalence of bipolar disorders: Traditional and novel approaches. Clinical Approaches in Bipolar Disorders 2002; 1: 10-14.
6. Freeman MP, Arnold LM, McElroy SL. Bipolar disorder. In: Kornstein SG, Clayton AH, eds. Women's mental health. New York: Guilford, 2002: 166-181.
7. Mitchell PB, Slade T, Andrews G. Twelve-month prevalence and disability of DSM-IV bipolar disorder in an Australian general population survey. Psychological Medicine 2004; 34: 777-785.
8. Leibenluft E. Women with bipolar illness: Clinical and research issues. American Journal of Psychiatry 1996; 153: 163-173.
9. Arnold LM, McElroy SL, Keck PE. The role of gender in mixed mania. Comprehensive Psychiatry 2000; 41: 83-87.
10. McElroy SL, Keck PE Jr, Pope HG Jr et al. Clinical and research implications of the diagnosis of dysphoric or mixed mania or hypomania. American Journal of Psychiatry 1992; 149: 1633-1644.
11. Goodwin FK, Jamison KR, eds. Manic-depressive illness. New York: Oxford University Press, 1990.
12. Nair SRN, O'Reardon JP, Sethi SS, Amsterdam JD. Bipolar disorder: For women a mixed picture. Psychiatric Annals 2000; 30: 465-471.
13. Zornberg GL, Pope HG Jr. Treatment of depression in bipolar disorder new directions for research. Journal of Clinical Psychopharmacology 1993; 13: 397-408.
14. Tohen M, Greenfield SF, Weiss RD et al. The effect of co-morbid substance use disorders on the course of bipolar disorder: A review. Harvard Review Psychiatry 1998; 6: 133-141.
15. Sasson Y, Chopra M, Harrari E, Amitai K, Zohar J. Bipolar comorbidity; from diagnostic dilemmas to therapeutic challenge. International Journal of Neuropsychopharmacology 2003; 6: 139-144.
16. Strakowski SM, Tohen M, Stoll A et al. Comorbidity in mania at first hospitalization. American Journal of Psychiatry 1992; 149: 554-556.
17. Bottlender R, Jager M, Straub A et al. Suicidality in bipolar compared to unipolar depressed inpatients. European Archives of Psychiatry and Clinical Neuroscience 2000; 250: 257-261.
18. Regier DA, Farmer ME, Rae DS et al. Co-morbidity of mental disorders with alcohol and other drug abuse: Results from the Epidemiologic Catchment Area Study (ECA). The Journal of the American Medical Association 1990; 264: 2511-2518. [Abstract].
19. Kraeplin E. Manic-depressive insanity and paranoia. Edinburgh: Livingstone, 1921.
20. Sonne SC, Brady KT, Morton WA. Substance abuse and bipolar affective disorder. Journal of Nervous Mental 1994; 182: 349-352.
21. Frye MA, Altshuler LL, McElroy SL et al. Gender differences in prevalence, risk, and clinical correlates of alcoholism co-morbidity in bipolar disorder. American Journal of Psychiatry 2003; 160: 883-889.
22. Sasson Y, Chopra M, Harrari E. Bipolar co morbidity; from diagnostic dilemmas to therapeutic challenge. International Journal of Neuropsychopharmacol 2003; 6: 139-144.
23. Harris EC, Barraclough B. Suicide as and outcome for mental disorders: A meta-analysis. Bristish Journal of Psychiatry 1997; 170: 205-228.
24. Malhi G, Mitchell PB, Salim S. Bipolar depression; management options. CNS Drugs 2003; 17: 9-25.
25. Dalton EJ, Cate-Carter TD, Mundo E et al. Suicide risk in bipolar patients: The role of co-morbid substances use disorders. Bipolar Disorders 2003; 5: 58-61.
26. Dunner DL, Fieve RR. Clinical factors in lithium carbonate prophylaxis failure. Archives of General Psychiatryl 1974; 30: 229-233.
27. Leibenluft E. Women and bipolar disorder: An update. Bulletin of the Menninger Clinic 2000; 64: 5-17.
28. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edn. Washington, DC: American Psychiatric Press, 1994.
29. Akiskal HS. The prevalent clinical spectrum of bipolar disorders; beyond the DSM-IV. Journal of Clinical Psychopharmacology 1996; 16: 4S-14S.
30. Kessler RC, Mc Gongle KA, Swartz M et al. Sex and depression in the National Co-morbidity study I: A lifetime prevalence, chronicity and recurrence. Journal of Affective Disorders 1993; 29: 85-96.
31. Stahl SM. Basic psychopharmacology of antidepressants: Part 2. Estrogen as an adjunct to antidepressant treatment. Journal of Clinical Psychiatry 1998; 59 (Suppl): 15-24.
32. Frankhauser MP. Psychiatric disorders in women: Psychopharmacologic treatments. Journal of American Pharmacological Association (Washington) 1997; 37: 667-678.
33. Sanborn K, Jefferson JW. Everyman's guide to the fluctuating lithium level. Obvious and obscure reasons why serum lithium levels change. Annals of Clinical Psychiatry 1991; 3: 251-258.
34. Yonkers KA, Hamilton JA. Sex differences in pharmacokinetics of psychotropic medications: II. Effects on selected psychotropics. In: Jensvold MF, Halbreich V, eds. Psychopharmacology and women: Sex, gender and hormones. Washington, DC: American Psychiatric Press, 1996: 43-71.
35. Kornstein SG, Schatzberg AF, Thases ME et al. Gender differences in treatment response to sertraline verus imipramine in chronic depression. American Journal of Psychiatry 2000; 157: 1445-1452.
36. Davidson J, Pelton S. Forms of atypical depression and their response to antidepressant drugs. Psychiatry Research 1986; 17: 87-95.
37. Hildebrandt MG, Steyerberg EW, Stage K et al. Are gender differences important for the clinical effects of antidepressants?American Journal of Psychiatry 2003; 160: 1643-1650.
38. McCall WV, Shelp FE, Weiner RD et al. Convulsive thresholds in right unilateral and bilateral ECT. Biological Psychiatry 1993; 34: 606-611.
39. Sackheim HA, Portnoy S, Neeley P et al. Cognitive consequences of low dosage electroconvulsive therapy. Annals of New York Academy of Sciences 1986; 462: 326-340.
40. Thase ME, Frank E, Kornstein SG et al. Sex-related differences in response to treatments of depression. In: Frank E, ed. Gender and its effects on psychopathology. Washington, DC: American Psychiatric Press, 2000: 103-129.
41. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder. American Journal of Psychiatry 2002; 151: 1-36.
42. Mitchell PB, Malhi GS, Redwood BL, Ball J for the RANZCP Clinical Practice Guideline Team for Bipolar Disorder. Summary of guideline for the treatment of bipolar disorder. Australasian Psychiatry 2003; 11: 39-53.
43. Isojarvi JI, Laatikainen TJ, Pakarinen AJ et al. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. New England Journal of Medicine 1993; 329: 1383-1388.
44. Ragson NL, Altshuler LL, Gudeman D et al. Medication status and polycystic ovary syndrome in women with bipolar disorder: A preliminary report. Journal of Clinical Psychiatry 2000; 61: 173-178.
45. O'Donovan C, Kusumakar V, Graves GR, Bird DC. Menstrual abnormalities and polycystic ovary syndrome in women taking valproate for bipolar mood disorder. Journal of Clinical Psychiatry 2002; 63: 322-330.
46. Shenfield GM. Oral contraceptives: Are drug interactions of clinical significance?Drug Safety 1993; 9: 21-37.
47. Calabrese JR, Vieta E, Shelton MD. Latest maintenance data on lamotrigine in bipolar disorder. European Neuropsychopharmacology 2003; 13: 57-66.
48. Bowden C, Calabrese JR, Sachs G et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar disorder. Archives of General Psychiatry 2003; 60: 392-400.
49. Ahokas A, Kaukoranta J, Aito M. Effect of oestradiol on postpartum depression. Psychopharmacology 1999; 146: 108-110.
50. Ernst C, Goldberg JF. The reproductive safety profile of mood stabilizers, atypical antipsychotics and braid spectrum psychotropics. Journal of Clinical Psychiatry 2002; 63 (Suppl 4): 42-55.
51. Tohen M, Ketter TA, Zarate CA et al. Olanzapine verus divalproex sodium for the treatment of acute mania and the maintenance of remission: A 47 weeks study. American Journal of Psychiatry 2003; 160: 1263-1271.
52. Zohar J, Shapira B, Oppenheim G et al. Addition of estrogen to impramine in female resistant depressives. Psychopharmacology Bulletin 1985; 21: 705-706.
53. Oppenheim G. A case of rapid mood cycling with estrogen: Implications for therapy. Journal of Clinical Psychiatry 1984; 45: 34-35.
54. Halbreich U, Kahn LS. Role of estrogen in the aetiology and treatment of mood disorders. CNS Drugs 2001; 15: 797-817.
55. Chouinard G, Steinberg S, Steiner W. Estrogen-progesterone combination: another mood stabilizer?American Journal of Psychiatry 1987; 144: 826.
56. Meakin C, Brockington IF. Failure of progesterone treatment in puerperal mania. British Journal of Psychiatry 1990; 156: 910.
57. Oppenheim G. A case of rapid cycling mood cycling with estrogen: implications for therapy. Journal of Clinical Psychiatry 1984; 45: 34-35.
58. Horrobin DF, Bennett CN. Depression and bipolar disorder; relationships to impaired fatty acid and phospholipid metabolism and to diabetes, cardiovascular disease, immunological abnormalities, cancer, ageing and osteoporosis. Possible candidate genes. Prostaglandins Leukotrienes and Essential Fatty Acids 1999; 60: 217-234.
59. Stoll AL, Severus WE, Freeman MP et al. Omega-3 fatty acids in bipolar disorder: A preliminary double blind, placebo controlled trial. Archives of General Psychiatry 1999; 56: 407-412.
60. Wisner KL, Peindl KS, Perel JM et al. Verapamil treatment for women with bipolar disorder. Biological Psychiatry 1994; 271: 146-150.
61. Cohen LS, Friedman JM, Jefferson JW, Johnson EM, Weiner ML. A re-evaluation of risk in utero exposure of lithium. The Journal of the American Medical Association 2002; 51: 745-752.
62. Yonkers KA, Wisner KL, Stowe Z et al. Management of bipolar disorder during pregnancy and the postpartum period. American Journal of Psychiatry 2004; 161: 608-620.
63. Roas FW. Spina bifida in infants of women treated with carbamazepine during pregnancy. New England Journal of Medicine 1991; 324: 674-677.
64. Llewellyn A, Stowe ZN, Strader JR Jr. The use of lithium and management of women with bipolar disorder during pregnancy and lactation. Journal of Clinical Psychiatry 1998; 59 (Suppl 6): 57-64.
65. Iqbal MM, Gundlapali SP, Ryan WG et al. Effects of antimanic mood-stabilising drugs in fetuses, neonates and nursing infants. South Medical Journal 2001; 94: 304-322.
66. Lamotrigine Pregnancy Registry Interim Report. 1 September 1992 through 30 September 2001. Wilmington, NC, Pharmaresearch 1-910-256-0549.
67. Macdonald KJ, Young LT. Newer antiepileptic drugs in bipolar disorder rationale for use and role in therapy. CNS Drugs 2002; 16: 549-562.
68. Altshuler LL, Cohen L, Szuba MP et al. Pharmacologic management of psychiatric illness in pregnancy: Dilemmas and guidelines. American Journal of Psychiatry 1996; 153: 592-606.
69. Kulin NA, Pastuszak A, Koren G. Pregnancy outcome following maternal use of new selective serotonin reuptake inhibitors: A prospective multi-center controlled study. The Journal of the American Medical Association 1998; 279: 609-610.
70. Wisner KL, Gelenberg AJ, Leonard H et al. Pharmacologic treatment of depression during pregnancy. The Journal of the American Medical Association 1999; 282: 1264-1269.
71. Leibenluft E. Issues in the treatment of women with bipolar illness. Journal of Clinical Psychiatry 1997; 58: 5-11.
72. Laine K, Heikkinen T, Ekblad U et al. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Archives of General Psychiatry 2003; 60: 720-726.
73. Amsterdam JD, Garcia-Espana F. Venlafaxine monotherapy in women with bipolar II and unipolar major depression. Journal of Affective Disorders 2000; 59: 225-229.
74. Chaudron LH, Jefferson JW. Mood stabilizers during breast-feeding: A review. Journal of Clinical Psychiatry 2000; 61: 79-90.
75. Schou M, Amidsen A. lithium and pregnancy: III. Lithium ingestion by children breast-fed by women on lithium treatment. British Medical Journal 1973; 2: 138.
76. Sykes PA, Quarrie J, Alexander FW. Lithium carbonate and breast feeding. British Medical Journal 1976; 2: 1299.
77. Burt VK, Suri R, Altshuler L et al. The use of psychotropic medications during breast-feeding. American Journal of Psychiatry 2001; 158: 1001-1009.
78. Frey B, Schubiger G, Musy JP. Transient cholestatic hepatitis in a neonate associated with carbamazepine exposure during pregnancy and breastfeeding. European Journal of Paediatrics 1990; 150: 136-138.
79. Wisner KL, Perel JM. Serum levels of valproate and carbamazepine in breast-feeding. Journal of Clinical Psychopharmacology 1998; 18: 167-169.
80. Stahl MM, Neiderud J, Vinge E. Thrombocytopenic purpura and anaemia in a breast-fed infant whose mother was treated with valproic acid. Journal of Paediatrics 1997; 130: 1001-1003.
81. Hendrick V, Altshuler LL, Burt VK. Course of psychiatric disorders across the menstrual cycle. Harvard Review of Psychiatry 1996; 4: 200-207.
82. Ragson N, Bauer M, Elman GT et al. Menstrual cycle related mood changes in women with bipolar disorder. Bipolar Disorders 2003; 5: 48-52.
83. Diamond SB, Rubinstein AA, Dunner DL et al. Menstrual problems in women with affective illness. Comprehensive Psychiatry 1976; 17: 541-548.
84. Blehar Mc, DePaulo JR Jr, Gershon ES et al. Women with bipolar disorder: findings from the NIMH genetics initiative sample. Psychopharmacology Bulletin 1998; 34: 239-243.
85. Leibenluft E, Ashman SB, Feldman-Naim S et al. Lack of relationship between menstrual cycle phase and mood ina sample of women with rapid cycling bipolar disorder. Biological Psychiatry 1999; 46: 577-580.
86. Kendell RE, Chalmers JC, Platz C. Epidemiology of puerperal psychoses. British Journal of Psychiatry 1987; 150: 662-673.
87. Grof P, Robbins W, Alda M et al. Protective effect of pregnancy in women with lithium-responsive bipolar disorder. Journal of Affective Disorders 2000; 61: 31-39.
88. Viguera AC, Cohen LS, Baldessarini RJ et al. Managing bipolar disorder during pregnancy: Weighing the risks and benefits. Canadian Journal of Psychiatry 2002; 47: 426-436.
89. Viguera AC, Nonacs R, Cohen LS et al. Risk of recurrence of bipolar disorder in pregnant and non-pregnant women after discontinuation lithium maintenance. American Journal of Psychiatry 2000; 157: 179-184.
90. Freeman MP, Wosnitzer Smith K, Freeman SA et al. The impact of reproductive events on the course of bipolar disorder in women. Journal of Clinical Psychiatry 2002; 63: 284-287.
91. Hunt N, Silverstone T. Does puerperal illness distinguish a subgroup of bipolar patients?Journal of Affective Disorders 1995; 34: 101-107.
92. Wisner KL, Peindl K, Hanusa BH. Symptomatology of affective and psychotic illness related to childbearing. Journal of Affective Disorders 1993; 30: 77-87.
93. Brockington IF, Cernik KF, Schofield EM et al. Puerperal psychosis: phenomena and diagnosis. Archives of General Psychiatry 1981; 38: 829-833.
94. Gregoire A, Kumar R, Everitt B et al. Transdermal oestrogen for the treatment of severe postnatal depression. Lancet 1996; 347: 930-933.
95. Sichel DA, Cohen LS, Robertson LM et al. Prophylactic estrogen in recurrent postpartum affective disorder. Biological Psychiatry 1995; 38: 814-818.
96. Jones I, Craddock N. Familiarity of the puerperal trigger in bipolar disorder: Results of a family study. American Journal of Psychiatry 2001; 158: 913-917.
97. Hunt N, Trevor S. Dose puerperal illness distinguish a subgroup of bipolar patients?Journal of Affective Disorders 1995; 34: 101-107.
98. Reich T, Winokur G. Postpartum psychoses in patients with manic depressive disorder. Journal of Nervous and Mental Disorders 1970; 151: 60.
99. Parry B. Reproductive factors affecting the course of affective illness in women. Psychiatric Clinics of North America 1989; 12: 207-219.
100. Haynes P, Parry BL. Mood disorders and the reproductive cycle: Affective disorders during the menopause and premenstrual dysphoric disorder. Psychopharmacological Bulletin 1998; 34: 313-318.
101. Viguera AC, Cohen LS. The course and management of bipolar disorder during pregnancy. Psychopharmacological Bulletin 1998; 34: 339-346.
102. Bauer M, Ahrens B. Bipolar disorder: A practical guide to drug treatment. CNS Drugs 1996; 6: 35-52.
103. Cohen LS, Sichel DA, Robertson LM et al. Postpartum prophylaxis for women with bipolar disorder. American Journal of Psychiatry 1995; 152: 1641-1645.
104. Austin M-PV. Puerperal affective psychosis: Is there a case for lithium prohylaxis?British Journal of Psychiatry 1992; 161: 692-694.
105. Davenport YB, Adland ML. Postpartum psychoses in female and male bipolar manic-depressive patients. American Journal of Orthopsychiatry 1982; 52: 288-297.
106. Leibenluft E, Albert PS, Rosenthal NE et al. The relationship between sleep and mood in patients with rapid cycling bipolar disorder. Psychiatric Research 1996; 63: 161-168.